Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
$9.02
-$0.02(-0.25%)
At close: 4:00 PM EST
$9.02
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$6.00 - $11.31
Previous CloseN/A
Volume537.69K
Average Volume (3M)6.34M
Market Cap
$2.26B
Enterprise Value$2.28B
Total Cash (Recent Filing)$274.75M
Total Debt (Recent Filing)$477.33M
Price to Earnings (P/E)6.2
Beta0.73
Next Earnings
Apr 30, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.12
Shares Outstanding250,800,610
10 Day Avg. Volume7,417,352
30 Day Avg. Volume6,344,901
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-13.74
Price to Sales (P/S)1.87
P/FCF Ratio5.00
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.61
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda6.49
Forecast
1Y Price Target
$21.63Price Target Upside139.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.27
Revenue Forecast (FY)$650.76M
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceStrong Orladeyo sales that have matched or exceeded company expectations support continued commercial momentum, while a simplified U.S.-focused operating model may improve margin potential.
Late-stage Clinical CatalystAn upcoming Phase 3 readout for navenibart, an acquired plasma kallikrein antibody with less frequent dosing, could materially expand prophylactic market share if efficacy and safety are confirmed.
Orphan And Pediatric Pipeline ExpansionProgress in the orphan-disease pipeline, including early patient data for BCX17725 in Netherton syndrome and expansion into the pediatric HAE segment, could open new addressable markets and diversify long-term revenue streams.
Bears Say
Acquisition Financing RiskThe acquisition financed with a mix of cash, debt and equity introduces financial leverage and potential shareholder dilution, which could pressure the stock if integration costs rise.
Competitive OverlapOverlap between Orladeyo and the newly added navenibart creates uncertainty about peak sales and market share, leaving valuation sensitive to how prescribing patterns evolve.
Margin Pressure And Growth ModerationExpectations for moderated growth combined with higher operating expenses tied to the acquisition could weigh on margins and limit near-term upside from earnings results.
BioCryst News
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $6.00 and its highest was $11.31 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $2.26B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 26 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Feb 26, 2026. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.048 by $1.072.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is 0.05.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 250,800,610 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of $1.12 in its last earnings report, beating expectations of $0.048. Following the earnings report the stock price went up 4.636%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.63 (139.80% Upside)
$21.63 (139.80% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 23.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $504.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.37%
12-Months-Change
Fundamentals
Return on Equity
-76.45%
Trailing 12-Months
Asset Growth
4.84%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BCRX Company Deck
BCRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum, record profitability, solid balance sheet and financing, successful pediatric approval, and highly encouraging clinical data for Navenibart and BCX17725. Management emphasized disciplined capital allocation, profitability, and scalable commercialization. Near-term headwinds include a seasonal Q1 reauthorization impact, rising 2026 R&D spend to support late-stage activities, uncertainty in pediatric uptake timing, and exposure of Navenibart regulatory timing to enrollment and data milestones. Overall, the positives — strong growth, record non-GAAP operating profit (+198% YoY), robust clinical efficacy (Navenibart mean attack reductions ~90%+, median 97%), and solid liquidity — outweigh the manageable near-term challenges.View all BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$21.63
▲(139.80% Upside)
Technical Analysis
Ownership Overview
1.55% Insiders
13.84% Mutual Funds
29.89% Other Institutional Investors
37.99% Public Companies and Individual Investors